Comparative Pharmacology
Head-to-head clinical analysis: RETIN A versus TAZORAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RETIN A versus TAZORAC.
RETIN-A vs TAZORAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retin-A (tretinoin) binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene expression involved in cell differentiation, proliferation, and inflammation. It increases epidermal turnover, reduces comedone formation, and stimulates collagen synthesis.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
Apply a thin layer to affected areas once daily at bedtime. Initial concentration typically 0.025% cream or 0.01% gel; titrate based on tolerability.
Apply a pea-sized amount to affected areas once daily in the evening. Tazorac is available as a 0.05% or 0.1% gel or cream. For plaque psoriasis, the 0.1% gel is typically used. For acne, the 0.1% cream or gel is started, then decreased to 0.05% if irritation occurs.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5-2 hours for the parent drug. Clinical context: Due to rapid clearance, systemic accumulation is negligible with topical use; effects persist due to retinoid-induced gene expression changes.
Terminal elimination half-life of tazarotenic acid is approximately 18 hours (range 7-30 hours) after topical application, allowing once-daily dosing; systemic exposure is low due to extensive protein binding and slow clearance.
After topical application, systemic absorption is minimal. The absorbed fraction is metabolized in the liver via cytochrome P450 enzymes and excreted in bile and urine as glucuronide conjugates. Renal excretion accounts for <1% of the applied dose; fecal excretion of metabolites is the primary route (<5% of applied dose).
Primarily fecal: approximately 60-70% eliminated in feces (as metabolites), renal excretion accounts for <10% as unchanged drug and metabolites, with <1% as unchanged tazarotenic acid.
Category C
Category C
Topical Retinoid
Topical Retinoid